Patron Partners LLC Purchases 69 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Patron Partners LLC raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,845 shares of the medical equipment provider’s stock after buying an additional 69 shares during the quarter. Patron Partners LLC’s holdings in Intuitive Surgical were worth $821,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Sivia Capital Partners LLC boosted its stake in Intuitive Surgical by 6.1% in the second quarter. Sivia Capital Partners LLC now owns 781 shares of the medical equipment provider’s stock valued at $347,000 after acquiring an additional 45 shares in the last quarter. Lake Street Advisors Group LLC lifted its holdings in shares of Intuitive Surgical by 3.2% during the 2nd quarter. Lake Street Advisors Group LLC now owns 2,924 shares of the medical equipment provider’s stock valued at $1,301,000 after purchasing an additional 91 shares during the last quarter. Account Management LLC acquired a new stake in shares of Intuitive Surgical in the 2nd quarter worth $2,347,000. UNIVEST FINANCIAL Corp grew its stake in Intuitive Surgical by 57.8% during the 2nd quarter. UNIVEST FINANCIAL Corp now owns 977 shares of the medical equipment provider’s stock worth $435,000 after buying an additional 358 shares during the last quarter. Finally, Private Advisor Group LLC grew its stake in Intuitive Surgical by 18.1% during the 2nd quarter. Private Advisor Group LLC now owns 14,019 shares of the medical equipment provider’s stock worth $6,236,000 after buying an additional 2,146 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $471.82 on Friday. The firm has a 50-day simple moving average of $458.74 and a two-hundred day simple moving average of $417.98. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $493.97. The company has a market cap of $167.35 billion, a P/E ratio of 85.17, a price-to-earnings-growth ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ISRG. Morgan Stanley increased their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Truist Financial lifted their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Citigroup lifted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Robert W. Baird boosted their price target on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Insider Activity

In related news, EVP Robert Desantis sold 239 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,293,799.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Robert Desantis sold 239 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,293,799.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. The disclosure for this sale can be found here. Insiders have sold 51,656 shares of company stock worth $24,700,644 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.